Lilly may yet squeeze some lemonade out of Phase III solanezumab lemons
This article was originally published in Scrip
Executive Summary
It will be months before Eli Lilly knows whether the encouraging signals in its Phase III studies for solanezumab are good enough for the US FDA to sign off on additional clinical trials with new primary endpoints, but analysts, patient groups and biotech firms cheered the company's announcement that its Alzheimer's therapy missed cognitive and functional primary endpoints yet showed positive activity in patients with mild forms of the disease.